Patients should be referred to endocrinology for CAH treatment in order to prevent the development of adrenal neoplasia, particularly myelolipoma secondary to increased adrenocorticotropic hormone (ACTH) [3,4]. The gene discussed is POMC; the disease is adrenal gland myelolipoma.